Ukko key facts
as of Oct 2026- Developer of immunity-boosting proteins designed to improve the lives of people who suffer from food allergies and gluten-related disorders.
- Ukko is valued at approximately $82.0M as of Oct 2026 (last reported valuation).
- It has raised $104.7M; the latest was Later Stage VC ($45.0M) in Jan 2026.
- Notable investors include Khosla Ventures, Western Technology Investment, OurCrowd, Slow Ventures, Innovation Endeavors — 21 tracked in total.
- Status: Privately Held (backing).
Ukko's last reported valuation, Jan 2021. Nothing priced has surfaced since.
- ·The complete investor list: 21 names
- ·Watch Ukko: the Monday email on marks, rounds and moves
Ukko funding rounds
No funding rounds for Ukko are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Ukko
21+Membership and data by Private Market View
Ukko valuation
Ukko's last reported valuation was $82 million in Jan 2021. No priced round, secondary trade or fund mark has surfaced since.
Ukko investors
21 investors are on record for Ukko, including Khosla Ventures, Western Technology Investment, OurCrowd and Slow Ventures. By type, the record holds 7 venture capital firms.
About Ukko
Developer of immunity-boosting proteins designed to improve the lives of people who suffer from food allergies and gluten-related disorders. The company's technology uses artificial intelligence, immunology, computational biology, and protein engineering to make safe proteins that do not trigger an immune response, enabling physicians to prescribe to people products that are safe to consume.
- Sector
- Healthcare
- HQ
- Mountain View, CA, United States
- Founded
- 2016
- Employees
- 62
- Website
- ukko.us/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.